Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -7.61 M

Cadrenal Therapeutics, Inc. Common Stock Net Income is USD -7.61 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 37.75% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Cadrenal Therapeutics, Inc. Common Stock Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -12.22 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years